CSIMarket
 


Neurocrine Biosciences Inc   (NBIX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

NBIX's Operating Income Growth by Quarter and Year

Neurocrine Biosciences Inc 's Operating Income results by quarter and year




NBIX Operating Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - -18.92 48.72 21.87
III Quarter September - -44.30 90.10 54.32
II Quarter June - 76.60 34.46 -1.85
I Quarter March 31.50 58.90 -101.00 -37.45
FY   31.50 72.28 72.28 36.89



NBIX Operating Income first quarter 2021 Y/Y Growth Comment
Neurocrine Biosciences Inc reported drop in Operating Income in the first quarter by -46.52% to $ 31.50 millions, from the same quarter in 2020.
The fall in the first quarter Neurocrine Biosciences Inc 's Operating Income compares unfavorably to the Company's average Operating Income jump of 76.23%.

Looking into first quarter results within Biotechnology & Drugs industry 19 other companies have achieved higher Operating Income growth. While Neurocrine Biosciences Inc ' s Operating Income meltdown of -46.52% ranks overall at the positon no. 1832 in the first quarter.

Explain Operating Income growth


NBIX Operating Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - - 122.77 % 84.87 %
III Quarter September - - 65.87 % -
II Quarter June - 122.29 % - -
I Quarter March -46.52 % - - -
FY   - 0 % 95.93 % -

Financial Statements
Neurocrine Biosciences Inc 's first quarter 2021 Operating Income $ 31.50 millions NBIX's Income Statement
Neurocrine Biosciences Inc 's first quarter 2020 Operating Income $ 58.90 millions Quarterly NBIX's Income Statement
New: More NBIX's historic Operating Income Growth >>


NBIX Operating Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - - -45.93 % -59.74 %
III Quarter September - - 161.46 % -
II Quarter June - 30.05 % - -
I Quarter March - 20.89 % - -
FY (Year on Year)   - 0 % 95.93 % -




Operating Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #20
Healthcare Sector #145
Overall #1832

Operating Income Y/Y Growth Statistics
High Average Low
370.42 % 76.23 % -48.99 %
(Sep 30 2019)   (Sep 30 2020)
Operating Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #20
Healthcare Sector #145
Overall #1832
Operating Income Y/Y Growth Statistics
High Average Low
370.42 % 76.23 % -48.99 %
(Sep 30 2019)   (Sep 30 2020)

Operating Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Neurocrine Biosciences Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
161.45 % 21.35 % -59.74 %
(Sep 30 2019)  


NBIX's I. Quarter Q/Q Operating Income Comment
I. Quarter 2021Periodic Neurocrine Biosciences Inc in the influence Operating Loss of $ 31.50 millionsPeriodic influence have contributed Neurocrine Biosciences Inc 's return to recovery, as NBIX postOperating Income of $ 31.50 millions in the I. Quarter 2021 emerging from Operating Loss-18.92 millions in the forth quarter. Neurocrine Biosciences Inc announced in the I. Quarter 2021 Operating Income of $ 31.50 millions compare to Operating Loss recorded in previos quarter.

Within Biotechnology & Drugs industry Neurocrine Biosciences Inc achieved highest sequential Operating Income growth. While Neurocrine Biosciences Inc 's Operating Income growth quarter on quarter, overall rank is 0.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0
Operating Income Q/Q Growth Statistics
High Average Low
161.45 % 21.35 % -59.74 %
(Sep 30 2019)  


NBIX's I. Quarter Q/Q Operating Income Comment
I. Quarter 2021Periodic Neurocrine Biosciences Inc in the factors Operating Loss of $ 31.50 millionsPeriodic factors seem to have led to Neurocrine Biosciences Inc 's restoration of profitability, as NBIX postOperating Income of $ 31.50 millions in the I. Quarter 2021 emanate Operating Loss-18.92 millions in the forth quarter. Neurocrine Biosciences Inc announced in the I. Quarter 2021 Operating Income of $ 31.50 millions compare to Operating Loss recorded in previos quarter.

Within Biotechnology & Drugs industry Neurocrine Biosciences Inc achieved highest sequential Operating Income growth. While Neurocrine Biosciences Inc 's Operating Income growth quarter on quarter, overall rank is 0.


Neurocrine Biosciences Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Operating Income 12 Months Ending $ 44.88 $ 72.28 $ 139.92 $ 274.32 $ 232.18
Y / Y Operating Income Growth (TTM) -80.67 % 0 % 207.97 % 2740.33 % -
Year on Year Operating Income Growth Overall Ranking # 1677 # 152 # 99 # 3 # 2010
Seqeuential Operating Income Change (TTM) -37.91 % -48.34 % -48.99 % 18.15 % 221.21 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1832 # 351 # 2150 # 97 # 2215




Cumulative Operating Income growth Comment
Neurocrine Biosciences Inc 's cumulative 12 months Operating Income continue to drop, but on the faster rate at -80.67% year on year, at Mar 31 2021 compare to the 0% decrease at Dec 31 2020. If the Neurocrine Biosciences Inc 's fiscal year would end at Mar 31 2021, annual Operating Income would be $45 millions.

In the Healthcare sector 116 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 152 to 1677.

Operating Income TTM Q/Q Growth Statistics
High Average Low
370.42 %
76.23 %
-48.99 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 20
Healthcare Sector # 117
Overall # 1677

Operating Income TTM Y/Y Growth Statistics
High Average Low
2740.33 %
505.45 %
-80.67 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 145
S&P 500 # 1832
Cumulative Operating Income growth Comment
Neurocrine Biosciences Inc 's cumulative 12 months Operating Income continue to drop, but on the faster rate at -80.67% year on year, at Mar 31 2021 compare to the 0% decrease at Dec 31 2020. If the Neurocrine Biosciences Inc 's fiscal year would end at Mar 31 2021, annual Operating Income would be $45 millions.

In the Healthcare sector 116 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 152 to 1677.

Operating Income TTM Q/Q Growth Statistics
High Average Low
370.42 %
76.23 %
-48.99 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 20
Healthcare Sector # 117
Overall # 1677

Operating Income TTM Y/Y Growth Statistics
High Average Low
2740.33 %
505.45 %
-80.67 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 145
S&P 500 # 1832




Other Operating Income Growth
Biotechnology & Drugs Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
NBIX's Operating Income Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for NBIX's Competitors
Operating Income Growth for Neurocrine Biosciences Inc 's Suppliers
Operating Income Growth for NBIX's Customers

You may also want to know
NBIX's Annual Growth Rates NBIX's Profitability Ratios NBIX's Asset Turnover Ratio NBIX's Dividend Growth
NBIX's Roe NBIX's Valuation Ratios NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio
NBIX's Roa NBIX's Inventory Turnover Ratio NBIX's Growth Rates NBIX's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2021
Petmed Express Inc-1.48%$ -1.480 millions
National Healthcare Corp-3.69%$ -3.689 millions
Prestige Consumer Healthcare Inc -4.03%$ -4.032 millions
Baxter International Inc -4.65%$ -4.645 millions
Davita Inc -4.89%$ -4.894 millions
Phibro Animal Health Corp-5.57%$ -5.568 millions
Steris Plc-7.41%$ -7.410 millions
Catalyst Pharmaceuticals Inc -8.40%$ -8.400 millions
Alexion Pharmaceuticals Inc -8.53%$ -8.526 millions
Diversified Healthcare Trust-18.14%$ -18.144 millions
Amneal Pharmaceuticals Inc -20.56%$ -20.564 millions
Healthcare Services Group Inc -21.26%$ -21.259 millions
Merck and Co Inc -22.90%$ -22.896 millions
Atrion Corporation-23.76%$ -23.758 millions
Msa Safety Inc-25.08%$ -25.083 millions
Acadia Healthcare Company Inc -26.43%$ -26.425 millions
Eli Lilly And Company-27.38%$ -27.376 millions
Stryker Corp-27.72%$ -27.717 millions
Millendo Therapeutics inc -29.44%$ -29.444 millions
Pacific Health Care Organization Inc-29.55%$ -29.552 millions
Lifevantage Corp-31.16%$ -31.157 millions
Teleflex Incorporated-34.15%$ -34.155 millions
Accuray Incorporated-44.46%$ -44.460 millions
Biogen Inc -46.49%$ -46.486 millions
Neurocrine Biosciences Inc -46.52%$ -46.520 millions
Corcept Therapeutics Inc-47.93%$ -47.925 millions
Vyne Therapeutics Inc -51.29%$ -51.287 millions
Supernus Pharmaceuticals inc -54.45%$ -54.453 millions
Nuvasive Inc-56.43%$ -56.429 millions
Five Star Senior Living Inc -57.53%$ -57.526 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AANC's Profile

Stock Price

AANC's Financials

Business Description

Fundamentals

Charts & Quotes

AANC's News

Suppliers

AANC's Competitors

Customers & Markets

Economic Indicators

AANC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071